Cargando…
Amygdalin as a chemoprotective agent in co-treatment with cisplatin
Amygdalin is a naturally occurring glycoside used in traditional Chinese medicine and is known to have anti-cancer properties. Even though the anti-cancer properties of amygdalin are well known, its effect on normal cells has not been thoroughly investigated. The aim of the present study was to inve...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531591/ https://www.ncbi.nlm.nih.gov/pubmed/36204233 http://dx.doi.org/10.3389/fphar.2022.1013692 |
_version_ | 1784801931763384320 |
---|---|
author | Christodoulou, Panayiota Boutsikos, Panagiotis Neophytou, Christiana M. Kyriakou, Theodora-Christina Christodoulou, Maria-Ioanna Papageorgis, Panagiotis Stephanou, Anastasis Patrikios, Ioannis |
author_facet | Christodoulou, Panayiota Boutsikos, Panagiotis Neophytou, Christiana M. Kyriakou, Theodora-Christina Christodoulou, Maria-Ioanna Papageorgis, Panagiotis Stephanou, Anastasis Patrikios, Ioannis |
author_sort | Christodoulou, Panayiota |
collection | PubMed |
description | Amygdalin is a naturally occurring glycoside used in traditional Chinese medicine and is known to have anti-cancer properties. Even though the anti-cancer properties of amygdalin are well known, its effect on normal cells has not been thoroughly investigated. The aim of the present study was to investigate a possible chemo-protective role of amygdalin against the cytotoxic effects of chemotherapy for normal human cells. Specifically, it was tested in combination with a strong chemotherapeutic drug cisplatin. Human non-tumorigenic MCF12F epithelial cell line, human fibroblasts cells, human breast cancer MCF7 and MDA-MB-231 cells were treated with cisplatin in a dose- and time-depended manner in the absence or presence of amygdalin. When MCF12F cells and fibroblasts underwent pre-treatment with amygdalin followed by cisplatin treatment (24 h amygdalin + 24 h cisplatin), the cell viability was increased (22%, p < 0.001) as indicated using MTT assay. As attested by flow cytometry, combination treatment was associated with decreased the percentage of late apoptotic cells compared with monotherapy (fold-change of decrease = 1.6 and 4.5 for 15 and 20 μΜ, respectively). Also, the proteins expression of PUMA, p53, phospho-p53 and Bax decreased, when a combination treatment was used vs. cisplatin alone, while the proapoptotic proteins Bcl-2 and Bcl-xL exhibited an increased tendency in the presence of amygdalin. Moreover, the levels of pro-apoptotic genes PUMA, p53, and BAX mRNA were significantly downregulated (∼83%, ∼66%, and ∼44%, respectively) vs. cisplatin alone, while the mRNA levels of anti-apoptotic genes BCl-2 and Bcl-XL were upregulated (∼44.5% and ∼51%, respectively), vs. cisplatin alone after 24 h of combination treatment. The study on the Combination index (CI) assay indicated that amygdalin could be possibly considered as an antagonist to cisplatin (2.2 and 2.3) for MCF12F and fibroblast cells, respectively. In contrast, for the breast cancer MCF7 and MDA-MB-231 cells, amygdalin and cisplatin indicated a synergistic effect (0.8 and 0.65), respectively. Our present findings suggest that amygdalin has chemo-modulatory effect when used in co-treatment with cisplatin and is able to protect normal breast cells as well as the fibroblasts during chemotherapy treatment, indicating a strong selective chemoprotective ability and may contribute to a better quality of life for cancer patients. |
format | Online Article Text |
id | pubmed-9531591 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95315912022-10-05 Amygdalin as a chemoprotective agent in co-treatment with cisplatin Christodoulou, Panayiota Boutsikos, Panagiotis Neophytou, Christiana M. Kyriakou, Theodora-Christina Christodoulou, Maria-Ioanna Papageorgis, Panagiotis Stephanou, Anastasis Patrikios, Ioannis Front Pharmacol Pharmacology Amygdalin is a naturally occurring glycoside used in traditional Chinese medicine and is known to have anti-cancer properties. Even though the anti-cancer properties of amygdalin are well known, its effect on normal cells has not been thoroughly investigated. The aim of the present study was to investigate a possible chemo-protective role of amygdalin against the cytotoxic effects of chemotherapy for normal human cells. Specifically, it was tested in combination with a strong chemotherapeutic drug cisplatin. Human non-tumorigenic MCF12F epithelial cell line, human fibroblasts cells, human breast cancer MCF7 and MDA-MB-231 cells were treated with cisplatin in a dose- and time-depended manner in the absence or presence of amygdalin. When MCF12F cells and fibroblasts underwent pre-treatment with amygdalin followed by cisplatin treatment (24 h amygdalin + 24 h cisplatin), the cell viability was increased (22%, p < 0.001) as indicated using MTT assay. As attested by flow cytometry, combination treatment was associated with decreased the percentage of late apoptotic cells compared with monotherapy (fold-change of decrease = 1.6 and 4.5 for 15 and 20 μΜ, respectively). Also, the proteins expression of PUMA, p53, phospho-p53 and Bax decreased, when a combination treatment was used vs. cisplatin alone, while the proapoptotic proteins Bcl-2 and Bcl-xL exhibited an increased tendency in the presence of amygdalin. Moreover, the levels of pro-apoptotic genes PUMA, p53, and BAX mRNA were significantly downregulated (∼83%, ∼66%, and ∼44%, respectively) vs. cisplatin alone, while the mRNA levels of anti-apoptotic genes BCl-2 and Bcl-XL were upregulated (∼44.5% and ∼51%, respectively), vs. cisplatin alone after 24 h of combination treatment. The study on the Combination index (CI) assay indicated that amygdalin could be possibly considered as an antagonist to cisplatin (2.2 and 2.3) for MCF12F and fibroblast cells, respectively. In contrast, for the breast cancer MCF7 and MDA-MB-231 cells, amygdalin and cisplatin indicated a synergistic effect (0.8 and 0.65), respectively. Our present findings suggest that amygdalin has chemo-modulatory effect when used in co-treatment with cisplatin and is able to protect normal breast cells as well as the fibroblasts during chemotherapy treatment, indicating a strong selective chemoprotective ability and may contribute to a better quality of life for cancer patients. Frontiers Media S.A. 2022-09-20 /pmc/articles/PMC9531591/ /pubmed/36204233 http://dx.doi.org/10.3389/fphar.2022.1013692 Text en Copyright © 2022 Christodoulou, Boutsikos, Neophytou, Kyriakou, Christodoulou, Papageorgis, Stephanou and Patrikios. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Christodoulou, Panayiota Boutsikos, Panagiotis Neophytou, Christiana M. Kyriakou, Theodora-Christina Christodoulou, Maria-Ioanna Papageorgis, Panagiotis Stephanou, Anastasis Patrikios, Ioannis Amygdalin as a chemoprotective agent in co-treatment with cisplatin |
title | Amygdalin as a chemoprotective agent in co-treatment with cisplatin |
title_full | Amygdalin as a chemoprotective agent in co-treatment with cisplatin |
title_fullStr | Amygdalin as a chemoprotective agent in co-treatment with cisplatin |
title_full_unstemmed | Amygdalin as a chemoprotective agent in co-treatment with cisplatin |
title_short | Amygdalin as a chemoprotective agent in co-treatment with cisplatin |
title_sort | amygdalin as a chemoprotective agent in co-treatment with cisplatin |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531591/ https://www.ncbi.nlm.nih.gov/pubmed/36204233 http://dx.doi.org/10.3389/fphar.2022.1013692 |
work_keys_str_mv | AT christodouloupanayiota amygdalinasachemoprotectiveagentincotreatmentwithcisplatin AT boutsikospanagiotis amygdalinasachemoprotectiveagentincotreatmentwithcisplatin AT neophytouchristianam amygdalinasachemoprotectiveagentincotreatmentwithcisplatin AT kyriakoutheodorachristina amygdalinasachemoprotectiveagentincotreatmentwithcisplatin AT christodouloumariaioanna amygdalinasachemoprotectiveagentincotreatmentwithcisplatin AT papageorgispanagiotis amygdalinasachemoprotectiveagentincotreatmentwithcisplatin AT stephanouanastasis amygdalinasachemoprotectiveagentincotreatmentwithcisplatin AT patrikiosioannis amygdalinasachemoprotectiveagentincotreatmentwithcisplatin |